Lixte Biotechnology Holdings
Open
$6.32
Prev. Close
$6.32
High
$6.32
Low
$6.20
Market Snapshot
$71.92M
-9.8
-1.59
2
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The company is headquartered in Boca Raton, Florida and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The firm is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The company is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The company is headquartered in Boca Raton, Florida and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The firm is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The company is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.
Recently from Cashu
Update on Lixte Biotechnology Holdings: Recent Developments and Future Outlook
Please provide the text you would like me to summarize, and I will gladly create a 300-word paragraph for you.
Lixte Biotechnology Holdings: Innovative Advances in Cancer Treatment and Research
Please provide the content you would like me to summarize, and I will gladly create a 300-word paragraph for you.
Lixte Biotechnology Holdings Advances Cancer Treatment with Innovative Research Findings
Lixte Biotechnology Advances Cancer Treatment with Promising Research Findings Lixte Biotechnology Holdings makes significant strides in the development of innovative cancer therapies through its rese…
Lixte Biotechnology Holdings Advances Cancer Treatment with LB-100 Clinical Trials
Lixte Biotechnology Advances Targeted Cancer Treatment with New Drug Trials Lixte Biotechnology Holdings, a company dedicated to the development of innovative cancer therapies, announces a significant…